Savara (NASDAQ:SVRA) Stock Price Down 6.5% – Should You Sell?

Savara Inc. (NASDAQ:SVRA)’s share price traded down 6.5% on Friday. The stock traded as low as $4.17 and last traded at $4.2450. Approximately 341,344 shares were traded during mid-day trading, a decline of 80% from the average session volume of 1,714,192 shares. The stock had previously closed at $4.54.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on SVRA shares. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. Royal Bank Of Canada set a $10.00 target price on shares of Savara in a report on Wednesday, October 7th. JPMorgan Chase & Co. began coverage on Savara in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research note on Thursday, October 15th. Finally, Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.25.

Savara Price Performance

The company has a market capitalization of $863.96 million, a price-to-earnings ratio of -7.27 and a beta of 0.20. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The company has a 50 day simple moving average of $5.16 and a 200 day simple moving average of $5.37.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). As a group, research analysts predict that Savara Inc. will post -0.66 EPS for the current year.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC boosted its holdings in Savara by 842.8% during the third quarter. Sterling Capital Management LLC now owns 5,063 shares of the company’s stock worth $26,000 after buying an additional 4,526 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new position in shares of Savara in the second quarter valued at approximately $69,000. WINTON GROUP Ltd bought a new position in Savara during the 2nd quarter worth about $151,000. Arizona State Retirement System grew its stake in shares of Savara by 34.0% during the 2nd quarter. Arizona State Retirement System now owns 25,445 shares of the company’s stock worth $157,000 after acquiring an additional 6,456 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Savara during the 2nd quarter worth about $194,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara’s lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.